Seagen Inc.
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 1998-01-01
- Employees
- 3.2K
- Market Cap
- -
- Website
- http://www.seagen.com
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
- Conditions
- Interventions
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 700
- Registration Number
- NCT05911295
- Locations
- 🇺🇸
Inova Schar Cancer Institute, Fairfax, Virginia, United States
🇧🇷Hospital de Cancer de Barretos - Fundacao Pio XII, Barretos, Other, Brazil
🇧🇷Centro de Oncologia da Bahia, Salvador, Other, Brazil
HER2 and LA/mUC: A Multi-country Chart Review Cohort Study
- Conditions
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 350
- Registration Number
- NCT05902494
- Locations
- 🇺🇸
Avera, Sioux Falls, South Dakota, United States
🇺🇸University of Colorado, Aurora, Colorado, United States
🇺🇸University of California San Francisco, San Francisco, California, United States
A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2022-10-07
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 275
- Registration Number
- NCT05571839
- Locations
- 🇺🇸
Mayo Clinic Arizona, Phoenix, Arizona, United States
🇺🇸The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸University of California Los Angeles Medical Center, Los Angeles, California, United States
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-02-24
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 400
- Registration Number
- NCT05253651
- Locations
- 🇺🇸
Palo Verde Cancer Specialists, Glendale, Arizona, United States
🇺🇸Mayo Clinic Arizona, Phoenix, Arizona, United States
🇺🇸Pacific Cancer Medical Center, Anaheim, California, United States
A Safety Study of Brentuximab Vedotin in Participants With HIV
- Conditions
- Interventions
- First Posted Date
- 2022-02-17
- Last Posted Date
- 2023-02-14
- Lead Sponsor
- Seagen Inc.
- Registration Number
- NCT05244473
- Locations
- 🇺🇸
University of California at San Francisco, San Francisco, California, United States
🇺🇸University of Illinois at Chicago, Chicago, Illinois, United States
A Study of SGN-ALPV in Advanced Solid Tumors
- First Posted Date
- 2022-02-08
- Last Posted Date
- 2023-12-28
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 43
- Registration Number
- NCT05229900
- Locations
- 🇺🇸
Women's Cancer Care, Fresno, California, United States
🇺🇸Virginia Cancer Specialists, Fairfax, Virginia, United States
🇨🇦University Health Network, Princess Margaret Hospital, Toronto, Ontario, Canada
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- First Posted Date
- 2022-01-26
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 438
- Registration Number
- NCT05208762
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Chao Family Comprehensive Cancer Center University of California Irvine, Orange, California, United States
🇺🇸University of California Davis, Sacramento, California, United States
A Study of SGN-B7H4V in Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2022-01-18
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 572
- Registration Number
- NCT05194072
- Locations
- 🇺🇸
University of Colorado Hospital / University of Colorado, Aurora, Colorado, United States
🇺🇸Sarah Cannon Research Institute at HealthONE - Denver, Denver, Colorado, United States
🇺🇸AdventHealth Cancer Institute, Celebration, Florida, United States
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-11-24
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 654
- Registration Number
- NCT05132582
- Locations
- 🇺🇸
CARTI Cancer Center, Little Rock, Arkansas, United States
🇪🇸Hospital Universitario Ramon y Cajal, Madrid, Other, Spain
🇺🇸Mayo Clinic Arizona, Phoenix, Arizona, United States
A Study of SEA-CD40 Given With Other Drugs in Cancers
- Conditions
- Interventions
- First Posted Date
- 2021-08-06
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 77
- Registration Number
- NCT04993677
- Locations
- 🇺🇸
Tennessee Oncology-Nashville/Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇺🇸Allina Health Cancer Institute, Minneapolis, Minnesota, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States